Anzeige
Mehr »
Login
Donnerstag, 06.03.2025 Börsentäglich über 12.000 News von 689 internationalen Medien
Eilmeldung: Trumps Krypto-Reserve löst Markt-Explosion aus - Pioneer AI Foundry setzt auf Solana!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A12CPC | ISIN: SE0005250719 | Ticker-Symbol: A6X
Frankfurt
05.03.25
08:25 Uhr
0,072 Euro
-0,005
-6,02 %
Branche
Chemie
Aktienmarkt
Sonstige
1-Jahres-Chart
AXICHEM AB Chart 1 Jahr
5-Tage-Chart
AXICHEM AB 5-Tage-Chart
GlobeNewswire (Europe)
55 Leser
Artikel bewerten:
(0)

aXichem AB: aXichem Announces Preliminary Findings from CrossFit Performance Study with aXivite, Indicating Unmatched Endurance and Recovery Gains

Finanznachrichten News

aXichem AB (publ), (aXichem), the developer of innovative natural analogue feed additives and food supplement ingredients, announces exciting preliminary results from its latest randomized, placebo-controlled, crossover study investigating the effects of aXivite® (phenylcapsaicin) on high-intensity CrossFit performance and recovery.

This study, conducted by Dr. Pablo Jiménez Martínez and his team in Spain, is part of a government-funded doctoral research initiative aimed at enhancing performance through novel bioactive compounds. Early data confirms that aXivite® significantly improves strength, endurance, and recovery, reinforcing its commercial potential in the rapidly expanding global sports nutrition market.

Key Preliminary Findings:

  • Increased Endurance: CrossFit athletes supplementing with aXivite® maintained performance levels significantly longer than those on placebo, demonstrating increased stamina and resilience in the final rounds of high-intensity CrossFit training sessions, commonly known as 'Workout of the Day' (WODs).
  • Peak Strength Gains: Participants taking aXivite® lifted more weight, completed more repetitions, and showed greater power output, even under conditions of extreme fatigue.
  • Accelerated Recovery: Athletes supplemented with PC reported reduced muscle soreness and a faster return to peak performance, a major factor in high-performance training and sports nutrition product selection.
  • AI-Driven Data Validation: This study introduces cutting-edge AI-based within-subject analysis, an unprecedented method in performance research, further solidifying the robustness of the findings.

Dr. Jiménez Martínez, the lead researcher, emphasized the significance of these findings:

"We anticipated phenylcapsaicin would enhance performance, but the results have exceeded our expectations. Even in the most grueling phases of CrossFit training, aXivite® consistently helped athletes push beyond fatigue, making it a standout ingredient in the sports performance category. Additionally, our ongoing sex-specific analysis could further highlight unique physiological benefits. I'm looking forward to full study results, which should be published in before the summer."

Lucas Altepost, Vice President of Sales and Marketing at aXichem, comments:

"These results confirm aXivite® as a category-defining innovation in the sports nutrition space. With demand for pre-workout and endurance-enhancing supplements surging across North America and Europe, this study provides the scientific validation that leading brands are actively seeking. We expect an increasing commercial interest from supplement manufacturers eager to integrate aXivite® into next-generation performance formulas."

About CrossFit and the sports nutrition market
CrossFit has evolved into one of the fastest-growing global fitness trends, with over 15,000 affiliated gyms worldwide and millions of active participants across North America, Europe, and beyond. The sport's intense, high-performance training style has created strong demand for effective nutritional supplements. The global sports nutrition market is projected to grow from $45 billion in 2023 to over $70 billion by 2030, with high-intensity performance supplements being one of the fastest-growing categories. aXivite®is strategically positioned to capitalize on this demand, offering a clinically backed, high-performance solution to brands looking to differentiate in the crowded supplement market.

The information was submitted, through the care of the contact person below, for publication on
5 March 2025, at 9:00 AM CET.

Company contact:
Torsten Helsing, CEO, aXichem AB
Phone: +46 706 863 355 Email: torsten.helsing@axichem.com

About aXichem
aXichem develops, patents and markets natural analogue industrial chemicals, i.e., synthetically produced substances that have similar and comparable properties to natural substances. The company's first product is phenylcapsaicin, which the company commercializes under two brands, aXiphen® and aXivite®, as an ingredient in animal feed and dietary supplements, respectively. The business is divided into three market areas with different applications for phenylcapsaicin: as an ingredient in feed for poultry, such as chicken and turkey; as an ingredient in food supplements for gut health, weight control and sports and exercise; and as an ingredient in food supplements for the bio- enhancement of curcumin and melatonin. aXichem is listed on the Nasdaq First North Growth Market. Certified advisor for aXichem is Västra Hamnen Corporate Finance AB.

More about aXichem at www.axichem.com.


© 2025 GlobeNewswire (Europe)
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.